Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada: concerns over teleradiology outsourcing from patients' point of view

This article was originally published in Clinica

Executive Summary

The availability of cheap outsourcing services for interpreting diagnostic images is putting patients' best interests at risk through blurring the line between business and medicine. So said Normand Laberge, CEO of the Canadian Association of Radiologists at the Canadian Medical Association's National Health Policy and Negotiations Conference recently. Although the service is essential for some regions in Canada that are facing staff shortages, rapid technological developments providing a growing number of effective interventions are pushing up the price of healthcare. As a result, "physicians become driven by business concerns rather than professional responsibilities" and may choose services by their price rather than their quality, he said.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT053463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel